scholarly journals Association of VEGF gene family variants with central macular thickness and visual acuity after Aflibercept short-term treatment in diabetic patients: A pilot study

2020 ◽  
Author(s):  
Ahmed A Abdelghany ◽  
Eman A Toraih ◽  
Ahmed A Mohamed ◽  
Rehab M Lashine ◽  
Mai H Saleh ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Pilot Study ◽  
Gene Family ◽  
Term Treatment ◽  
Macular Thickness ◽  
Diabetic Patients ◽  
Central Macular Thickness ◽  
Vegf Gene ◽  
Short Term ◽  
Short Term Treatment

Evaluation of a calculation model to estimate the impact of the COVID-19 pandemic lockdown on visual acuity in neovascular AMD

2021 ◽  
pp. 112067212110523
Author(s):  
Martin Stattin ◽  
Anna-Maria Haas ◽  
Daniel Ahmed ◽  
Alexandra Graf ◽  
Katharina Krepler ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Real Life ◽  
Treatment Interruption ◽  
Term Treatment ◽  
Calculation Model ◽  
Life Outcomes ◽  
Short Term ◽  
Short Term Treatment ◽  
The Real ◽  
The Impact

Purpose A model was calculated during the first Austrian coronavirus disease-2019 (COVID-19) pandemic lockdown to estimate the effect of a short-term treatment interruption due to healthcare restrictions on visual acuity (VA) in neovascular age-related macular degeneration (nAMD). The model was compared to the real-life outcomes before treatment re-started. Methods Retrospective data-collection of 142 eyes in 142 patients receiving repeated intravitreal injections with anti-VEGF at a retina unit in Vienna in a personalized pro-re-nata regimen prior to the COVID-19 associated lockdown, when treatment was deferred between March 16 and May 4, 2020. During the lockdown, the preliminary data was integrated into pre-existing formulae based on the natural course of the disease in untreated eyes in the long term. Patients were re-scheduled and treated after gradually opening operating rooms. The calculation model was compared to the effective VA change. Results The model calculated an overall VA loss of 3.5 ± 0.8 letters early treatment diabetes retinopathy study (ETDRS) ( p < 0.001 [95% CI:3.3;3.6]) on average compared to 2.5 ± 6 letters ETDRS ( p < 0.001 [95% CI:1.5;3.5]) as measured with a mean treatment delay of 61 ± 14 days after previously scheduled appointments. The total difference between the model exercise and the real-life outcomes accounted for 1 ± 5.9 letters ETDRS ( p = 0.051 [95% CI: 0.1;1.9]). Conclusion The herein presented calculation model might not be suitable to estimate the effective VA loss correctly over time, although untreated eyes and eyes under therapy show similarities after short-term treatment interruption. However, this study demonstrated the potentially negative impact of the COVID-19 pandemic lockdown on patients compromised by nAMD.

Short-term effect of aflibercept on visual acuity and central macular thickness in patients not responding to ranibizumab and bevacizumab

2016 ◽  
Vol 129 (9-10) ◽  
pp. 351-357
Author(s):  
Sandra Maksys ◽  
Sibylla Richter-Müksch ◽  
Birgit Weingessel ◽  
Pia Veronika Vécsei-Marlovits
Keyword(s):  
Visual Acuity ◽  
Term Effect ◽  
Macular Thickness ◽  
Central Macular Thickness ◽  
Short Term ◽  
Short Term Effect

Decrease in Lipoatrophy in a Pilot Study Using a Short-Term Treatment Interruption Strategy for 48 Weeks in São Paulo, Brazil

2012 ◽  
Vol 28 (8) ◽  
pp. 747-748
Author(s):  
Gisele Cristina Gosuen ◽  
Gilberto Turcato ◽  
Reinaldo Salomao ◽  
David Salomao Lewi ◽  
Ricardo Sobhie Diaz
Keyword(s):  
Pilot Study ◽  
Treatment Interruption ◽  
Sao Paulo ◽  
Term Treatment ◽  
São Paulo ◽  
Short Term ◽  
Short Term Treatment

Efficacy of Transdermal Clonidine in Short-Term Treatment of Cluster Headache: A Pilot Study

Cephalalgia ◽  
1995 ◽  
Vol 15 (5) ◽  
pp. 430-433 ◽  
Author(s):  
G. D'Andrea ◽  
F. Perini ◽  
F. Granella ◽  
A. Cananzi ◽  
A. Sergi
Keyword(s):  
Pilot Study ◽  
Cluster Headache ◽  
Term Treatment ◽  
Short Term ◽  
Short Term Treatment
Sign in / Sign up

Export Citation Format

Share Document